# Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

> **NCT01999673** · PHASE3 · COMPLETED · sponsor: **Peregrine Pharmaceuticals** · enrollment: 582 (estimated)

## Conditions studied

- Non-Small-Cell Lung Cancer Stage IIIB
- Non-Small-Cell Lung Cancer Stage IV
- Non-Small-Cell Lung Cancer Metastatic
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** bavituximab
- **DRUG:** Docetaxel
- **OTHER:** Placebo (for bavituximab)

## Key facts

- **NCT ID:** NCT01999673
- **Lead sponsor:** Peregrine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 582 (ESTIMATED)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01999673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01999673, "Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01999673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*